|
Singapore Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Singapore Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for Singapore .
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Singaporean pharmaceutical and healthcare industry.
Competitive intelligence, Singaporean pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Singaporean market.
The Singapore Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s Singapore Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Singaporean pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Singapore to test other views – a key input for successful budgeting and strategic business planning in the Singaporean pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Singaporean Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Singapore .
- Exploit The Latest Competitive Singaporean Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Singapore .
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
Singapore Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| SWOT Analysis |
| Singapore Pharmaceuticals And Healthcare Industry SWOT |
| Singapore Political SWOT |
| Singapore Economic SWOT |
| Singapore Business Environment SWOT |
Chapter - Pharmaceutical Business Environment Ratings |
| Table: Asia Pacific Pharmaceutical Business Environment Ratings for Q209 |
| Limits of Potential Returns |
| Risks to Realisation of Returns |
Chapter - Singapore – Market Summary |
| Regulatory Regime |
| Recent Regulatory Developments |
| Intellectual Property Issues |
| Trade Agreements |
| Pricing and Reimbursement |
Chapter - Industry Trends and Developments |
| Epidemiology |
| Table: Principal Causes Of Death In Singapore, 2004-2006 (as % of total deaths) |
| Healthcare Sector |
| Singapore's Trajectory In Quality And Patient Safety |
| Healthcare Company Developments |
| Healthcare Insurance Developments |
| Domestic Pharmaceutical Sector |
| Foreign Industry |
| Foreign Company Activities |
| Traditional Chinese Medicine |
| Supply Chain |
| Research and Development |
| Bioscience Sector |
| Recent Research and Development Activities |
| Clinical Trials |
| Recent Developments in Clinical Trials Industry |
| Medical Devices |
| Table: Classification Of Medical Devices In Singapore |
| Recent Developments in the Medical Devices Industry |
Chapter - Industry Forecast Scenario |
| Overall Market Forecast |
| Table: Singapore – Drug Expenditure Indicators, Historical Data and Forecasts |
| Key Growth Factors – Industry |
| Table: Singapore – Health Expenditure Indicators, Historical Data and Forecasts |
| Key Growth Factors – Macroeconomic |
| A Deep Recession In 2009 |
| Table: Singapore - Economic Activity |
| Prescription Market Forecast |
| Table: Singapore – Prescription Market Indicators, Historical Data and Forecasts (SGDmn unless otherwise stated) |
| Patented Drug Market Forecast |
| Table: Singapore – Patented Market Indicators, Historical Data and Forecasts |
| Generics Market Forecast |
| Table: Singapore – Generics Market Indicators, Historical Data and Forecasts |
| OTC Market Forecast |
| Table: Singapore – OTC Market Indicators, Historical Data and Forecasts (SGDmn unless otherwise stated) |
| Medical Device Market Forecast |
| Table: Singapore – Medical Device Market Indicators, Historical Data And Forecasts (US$mn unless otherwise stated) |
| Pharmaceutical Trade Forecasts |
| Table: Singapore – Pharmaceutical Trade Indicators, Historical Data and Forecasts (US$mn) |
| Other Healthcare Data Forecasts |
| Table: Singapore – Other Healthcare Indicators, Historical Data and Forecasts |
| Key Risks to BMI's Forecast Scenario |
Chapter - Competitive Landscape |
| Table: Singapore Pharmaceutical Market, 2006 |
Chapter - Company Profiles |
| Leading Multinationals |
| Pfizer |
| GlaxoSmithKline |
| Merck & Co |
| Novartis |
| Sanofi-Aventis |
| Baxter |
| Indigenous Manufacturers |
| Haw Par |
| SciGen |
| MerLion Pharmaceuticals |
| Veredus Laboratories |
Chapter - Country Snapshot: Singapore Demographic Data |
| Section 1: Population |
| Table: Demographic Indicators, 2005-2030 |
| Table: Rural/Urban Breakdown, 2000-2030 |
| Section 2: Education and Healthcare |
| Table: Education, 2000-2004 |
| Table: Vital Statistics, 2005-2030 |
| Section 3: Labour Market and Spending Power |
| Table: Employment Indicators, 2001-2006 |
| Table: Consumer Expenditure, 2000-2012 (US$) |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
Singapore Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
In BMI’s Business Environment Rankings (BER) matrix for Q209, Singapore retained its respectable fourth position out of the 15 key countries in the region, behind only the three most developed pharmaceutical markets in the region, namely Japan, Australia and South Korea. Positives include a 100% urban market, ageing population and a predictable operating climate, although its growth potential is limited, due to the small population size. In macroeconomic terms, the country’s policy continuity, economic structure and almost complete lack of corruption are great bonuses, with the country featuring in 20th spot in the BMI’s global pharmaceutical BER matrix for the quarter. Nevertheless, the absolute value of the Singapore’s pharmaceutical market – at some SGD808mn (US$561mn) in 2008 – remains small in global terms. Through 2013, the market is expected to develop at a minor compound annual growth rate (CAGR) of just 2.08% in local currency terms, to reach SGD895mn (US$631mn).
However, the fact that the government is continuing to make considerable investments in healthcare services bode well for pharmaceutical companies and providers of modern diagnostics and similar services. In February 2009, local press reported that the government of Singapore announced a SGD20.5bn (US$14.25bn) public-sector development programme, of which SGD4bn (US$2.8bn) has been earmarked for the modernisation of older hospitals and clinics, as well as the construction of new healthcare institutions. An additional SGD500mn (US$347mn) will be spent on elderly care, while the Ministry of Health has been allocated a SGD200mn (US$139mn) budget for the creation of a new electronic records system. Additionally, local pharmaceutical manufacturing output continues to defy the wider economic trends. In November 2008, while total manufacturing output in Singapore fell 7.5% yearon- year (y-o-y), due to an economic slowdown that impacted exports, pharmaceutical output rose 17.5%. Overall, biomedical output grew 14.9%.
Research and development (R&D) news have also been encouraging. In March 2009, global healthcare company PerkinElmer inaugurated its second Centre of Excellence at the Singapore’s A*STAR Biopolis research complex, which will provide life sciences training facilities for the Pacific Rim region scientific community. Similarly, earlier in 2009, US drug major Abbott Laboratories announced the opening of a new pharmaceutical analytical research laboratory, which will also be based at Biopolis and which will be used for the studies in the fields of active pharmaceutical ingredients (APIs) and novel formulations.
However, on a wider economic front, the recently released industrial and trade data suggest that 2009 will be a very painful year for Singapore. With economic growth weakening in its major trading partners including the US, EU and China, and limited potential for domestic demand to grow, Singapore will inadvertently be affected by declining trade volume. Consequently, we now forecast a GDP contraction of 2.8% in 2009, which will have a negative impact on out-of-pocket expenditure on drugs and healthcare services in general.
|
Singapore Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |